In short
Clinical trials are studying VERTEPORFIN in different patient groups, including men with newly diagnosed localised prostate cancer and people with surgical wounds at risk of scarring. These studies are looking at safety, early effectiveness, and the best dose or treatment settings. They also measure outcomes such as tissue damage, side effects, and scar quality.
Key points
- Clinical trials of VERTEPORFIN in the source data focus on two very different goals. One Phase 1 study is testing safety in men with newly diagnosed, organ-confined prostate cancer. Another Phase 2 study is testing whether different doses can help prevent scars after surgery. The prostate cancer trial measures toxicity, serious side effects, and MRI signs of tissue damage. The scar study measures scar quality after 3 months using POSAS. Both trials are interventional and are currently authorised.
Trial overview
The source data include two interventional studies, which means researchers give a planned treatment and then measure the results. One study is in people with primary localised prostate cancer, and the other is in people with surgical wounds to study scar prevention. Both studies are listed as Authorised.
Primary localised prostate cancer study
The first trial is an open-label Phase 1 study of the SpectraCure P18 System and verteporfin for injection in men with primary localised prostate cancer. Open-label means that people in the study and the research team know what treatment is being given. The study is designed for patients with organ-confined prostate cancer diagnosed within the last 9 months.
The brief summary says the main goal is to show that this approach is safe for patients with organ-confined prostate cancer and to find the safe maximum light threshold dose, starting at 20 J/cm2. A dose escalation plan is used, which means the treatment setting is increased step by step to find a safe level.
Scar prevention study
The second trial, called SCARFREE-001: Verteporfin for Scar Prevention, is a Phase 2 study. It is looking at whether intradermal VERTEPORFIN, meaning injection into the skin, can help prevent scars after surgery. The study includes scar formation following surgical wounds and compares VERTEPORFIN with saline, which is a placebo treatment used for comparison.
The study tests three doses of VERTEPORFIN: 0.5, 1.0, and 2.0 mg/mL. The goal is to learn whether there is a dose-response effect, which means whether higher or different doses change the result in a predictable way.
Outcomes and measures
In the prostate cancer study, the main outcome is safety, measured by toxicity using CTCAE v5.0 and by MRI checks for severe damage to the tissues around the prostate. The study also looks for no Grade 3 toxicity in the rectum or bladder and no drug-related serious adverse events as a sign of success.
In the scar prevention study, the main outcome is scar quality at 3 months. Researchers compare the three VERTEPORFIN doses with placebo in both sutured incision segments and punch biopsy wounds using the Observer part of the Patient and Observer Scar Assessment Scale, or POSAS.
Who may participate
Based on the trial data, the prostate cancer study is for people with newly diagnosed, localised disease that is still confined to the prostate and was diagnosed within the past 9 months. The scar prevention study is for people who have surgical wounds, including closed wounds and open punch biopsy wounds.
The trial records provided do not list every inclusion or exclusion rule, so the full eligibility details are not known from the source data alone.
What the results may mean
These trials are early steps in understanding whether VERTEPORFIN can be used in very different medical settings. In prostate cancer, the focus is on safety and tissue protection around the treatment area. In wound care, the focus is on whether VERTEPORFIN may improve the look and quality of scars after surgery.
Because one study is Phase 1 and the other is Phase 2, the data are still early and are mainly meant to guide future research rather than give final answers.